2023.12.11 VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL TRIALS OF CU-40102 (TOPICAL FINASTERIDE SPRAY) AND CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) IN THE PRC PUBLISHED AT THE 18TH CDA ANNUAL MEETING pdf-icon
2023.11.27 VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT COLLAGENASE) FOR ABDOMINAL ADIPOSE ACCUMULATION COMPLETED DATABASE LOCK pdf-icon
2023.11.06 OPERATIONAL UPDATE FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023 AND THIRD QUARTER OF 2023 pdf-icon
2023.11.02 VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF CU-40101 (TOPICAL SMALL MOLECULE THYROID HORMONE RECEPTOR AGONIST LINIMENT) IN CHINA REACHED PRIMARY ENDPOINT pdf-icon
2023.10.25 VOLUNTARY ANNOUNCEMENT - ALL ENROLLED PATIENTS COMPLETED PHASE I CLINICAL TRIAL OF CU-20401 (RECOMBINANT MUTANT COLLAGENASE) FOR ABDOMINAL ADIPOSE ACCUMULATION pdf-icon
2023.09.27 VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION pdf-icon
2023.09.07 VOLUNTARY ANNOUNCEMENT - REGISTRATIONAL PHASE III CLINICAL TRIAL OF CU-40102 (TOPICAL FINASTERIDE SPRAY) REACHED PRIMARY ENDPOINT pdf-icon
2023.09.05 VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE COMPANY IN THE LIST FOR SOUTHBOUND TRADING LINK UNDER THE SHANGHAI-HONG KONG STOCK CONNECT AND THE SHENZHEN-HONG KONG STOCK CONNECT pdf-icon
2023.08.29 INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2023 pdf-icon
2023.08.28 DISCLOSEABLE TRANSACTIONS - SUBSCRIPTIONS OF WEALTH MANAGEMENT PRODUCTS pdf-icon
2023.08.28 VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF CU-40101 (TOPICAL SMALL MOLECULE THYROID HORMONE RECEPTOR AGONIST LINIMENT) COMPLETED DATABASE LOCK pdf-icon
2023.08.23 VOLUNTARY ANNOUNCEMENT - ALL ENROLLED PATIENTS COMPLETED PHASE III CLINICAL TRIAL OF CU-30101 (LOCALIZED TOPICAL LIDOCAINE AND TETRACAINE CREAM) pdf-icon
2023.08.18 VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE COMPANY AS A CONSTITUENT STOCK OF THE HANG SENG FAMILY OF INDEXES pdf-icon
2023.08.17 DATE OF BOARD MEETING pdf-icon
2023.08.10 VOLUNTARY ANNOUNCEMENT - CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) HAS BEEN GRANTED PRIORITY REVIEW DESIGNATION BY THE CENTER FOR DRUG EVALUATION OF THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION pdf-icon
2023.08.02 OPERATIONAL UPDATE FOR THE SECOND QUARTER AND FIRST HALF OF 2023 pdf-icon
2023.07.18 VOLUNTARY ANNOUNCEMENT - ALL ENROLLED PATIENTS COMPLETED PHASE I CLINICAL TRIAL OF CU-40101 (TOPICAL SMALL MOLECULE THYROID HORMONE RECEPTOR AGONIST LINIMENT) pdf-icon
2023.07.05 STABILIZING ACTIONS, END OF STABILIZATION PERIOD AND LAPSE OF THE OVER-ALLOTMENT OPTION pdf-icon
2023.06.09 LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS pdf-icon
2023.06.09 Terms of Reference for the Nomination Committee pdf-icon
2023.06.09 Terms of Reference for the Remuneration Committee pdf-icon
2023.06.09 Terms of Reference for the Audit Committee pdf-icon
2023.06.09 ANNOUNCEMENT OF OFFER PRICE AND ALLOTMENT RESULTS pdf-icon
2023.05.31 GLOBAL OFFERING pdf-icon
2023.05.31 GREEN APPLICATION FORM pdf-icon
2023.05.31 GLOBAL OFFERING (Multi-Files) pdf-icon
2023.05.31 GLOBAL OFFERING pdf-icon